Last reviewed · How we verify
Gabapentin immediate release
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Postherpetic neuralgia, Partial-onset seizures (adjunctive therapy), Neuropathic pain.
At a glance
| Generic name | Gabapentin immediate release |
|---|---|
| Also known as | Neurontin |
| Sponsor | Theresa Zesiewicz, MD |
| Drug class | Anticonvulsant; gabapentinoid |
| Target | Voltage-gated calcium channel alpha-2-delta subunit |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By binding to presynaptic calcium channels, gabapentin decreases calcium influx and subsequently reduces the release of glutamate and other excitatory neurotransmitters. This leads to reduced neuronal excitability and is thought to underlie its analgesic and anticonvulsant effects. The exact mechanism in pain conditions remains incompletely understood but involves modulation of neuropathic pain pathways.
Approved indications
- Postherpetic neuralgia
- Partial-onset seizures (adjunctive therapy)
- Neuropathic pain
Common side effects
- Dizziness
- Somnolence
- Ataxia
- Fatigue
- Peripheral edema
- Tremor
Key clinical trials
- An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users (PHASE4)
- A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery (NA)
- Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD (PHASE2)
- Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome (PHASE4)
- Gabapentin Regimens and Their Effects on Opioid Consumption (PHASE4)
- Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabapentin immediate release CI brief — competitive landscape report
- Gabapentin immediate release updates RSS · CI watch RSS
- Theresa Zesiewicz, MD portfolio CI